Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections

Pediatric Infectious Disease Journal

Volumn 25, Issue 10, 2006, Pages 870-879

  Ashkenazi, Shai ^a   Vertruyen, Andre ^b   Arístegui, Javier ^c   Esposito, Susanna ^d   McKeith, David Douglas ^e   Klemola, Timo ^f   Biolek, Jiri ^g   Kühr, Joachim ^h   Bujnowski, Tadeusz ⁱ   Desgrandchamps, Daniel ^j   Cheng, Sheau Mei ^k   Skinner, Jonathan ^k   Gruber, William C ^k   Forrest, Bruce D ^k  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b Sint Vincentiusziekenhuis   (Belgium)

^c HOSPITAL DE BASURTO   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e Townhead Surgery   (United Kingdom)

^f UNIVERSITY OF HELSINKI   (Finland)

^g Hospital Most   (Czech Republic)

^h Clinic for Paediatric and Adolescent Medicine (Stadt Klinikrum Karlsruhe)   (Germany)

ⁱ Gabinet Prywatny   (Poland)

^j CHILDREN S HOSPITAL   (Switzerland)

^k WYETH RESEARCH   (United States)

more..

Author keywords

Children; Cold adapted influenza vaccine; Influenza; Respiratory tract infection; Trivalent

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; TRIPLE VACCINE;

ABDOMINAL PAIN; ARTICLE; CHILL; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; IRRITABILITY; MALE; MYALGIA; OTITIS MEDIA; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; RHINITIS; RHINORRHEA; SCHOOL; SIDE EFFECT; SORE THROAT; TREATMENT OUTCOME; VIRUS STRAIN; VOMITING; WHEEZING;

ADMINISTRATION, INTRANASAL; CHILD, PRESCHOOL; EATING DISORDERS; FEMALE; HUMANS; INCIDENCE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; ORTHOMYXOVIRIDAE; OTITIS MEDIA; RECURRENCE; RESPIRATORY TRACT INFECTIONS; RHINITIS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 33749428132     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000237829.66310.85     Document Type: Article

References (24)

1. Loughlin J, Poulios N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics. 2003;21:273-283.
2. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113(3 pt 1):585-593.
3. Forster J. Influenza in children: the German perspective. Pediatr Infect Dis J. 2003;22(10 suppl):S215-217.
4. Ploin D, Liberas S, Thouvenot D, et al. Influenza burden in children newborn to eleven months of age in a pediatric emergency department during the peak of an influenza epidemic. Pediatr Infect Dis J. 2003;22(10 suppl):S218-222.
5. Weigl JA, Puppe W, Schmitt HJ. The incidence of influenza-associated hospitalizations in children in Germany. Epidemiol Infect. 2002;129:525-533.
6. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23:189-197.
7. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003;290:1608-1616.
8. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733-740.
9. FluMist® (Influenza Virus Vaccine Live, Intranasal). Full Prescribing Information, MedImmune Vaccines, Inc., Gaithersburg, MD, 2004-2005 formulation.
10. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1405-1412.
11. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175.
12. Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002;21:44-48.
13. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138-144.
14. Chi XS, Bolar TV, Zhao P, Rappaport R, Cheng SM. Cocirculation and evolution of two lineages of influenza B viruses in Europe and Israel in the 2001-2002 season. J Clin Microbiol. 2003;41:5770-5773.
15. Chi XS, Bolar TV, Zhao P, et al. Molecular evolution of human influenza A/H3N2 virus in Asia and Europe from 2001 to 2003. J Clin Microbiol. 2005;43:6130-6132.
16. Recommended composition of influenza virus vaccines for use in the 2003-2004 influenza season. Wkly Epidemiol Rec. 2003;78:58-62.
17. Recommended composition of influenza virus vaccines for use in 2000. Wkly Epidemiol Rec. 1999;74:321-325.
18. Brammer L, Fukuda K, Arden N, et al. Centers for Disease Control and Prevention. Influenza surveillance: United States, 1992-93 and 1993-94. MMWR Morb Mortal Wkly Rep. 1997;46 (suppl SS1):1-12.
19. Vesikari T. Efficacy and safety of a cold-adapted, live attenuated, trivalent influenza vaccine (CAIV-T) in children aged 6 to <36 months attending day care centers in Europe and Israel (Abstract 1582). Paper presented at: Pediatric Academic Societies' 2005 Annual Meeting; May 14-17, 2005; Washington, DC.
20. Tam J, Capeding M, Lum L, et al. Efficacy of a live, attenuated influenza vaccine (CAIV-T) in children living in south east Asia against community acquired culture-confirmed influenza (Abstract #W03P-05). Paper presented at: Options for the Control of Influenza V; October 7-11, 2003; Okinawa, Japan.
21. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005;116:e397-407.
22. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
23. Principi N, Esposito S, Gasparini R, Marchisio P, Crovari P. Burden of influenza in healthy children and their households. Arch Dis Child. 2004;89:1002-1007.
24. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis. 2004;39:920-927.